No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Xalkori (crizotinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is associated with tumor growth. Xalkori is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic NSCLC with ALK-positive tumors. It is also approved for the treatment of ROS1-positive NSCLC.
Xalkori is a key drug in the lung cancer market, as it is the only approved therapy for ALK-positive NSCLC. It is also the only approved therapy for ROS1-positive NSCLC. Xalkori is a well-established drug, with a long history of clinical trials and a strong safety profile.
The Xalkori market is highly competitive, with several major pharmaceutical companies competing for market share. These include Pfizer, Merck, AstraZeneca, and Novartis. Other companies, such as Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly, also have a presence in the market. Show Less Read more
